Mucocutaneous features of autoimmune blistering diseases

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 84, Issue 5, 1997, Pages 517-534

  Weinberg, Mea A ^a   Insler, Michael S ^b   Campen, Rebecca B ^c  

^a NEW YORK UNIVERSITY   (United States)

^b LSU EYE CENTER   (United States)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN A;

ADULT; AUTOIMMUNE DISEASE; BASEMENT MEMBRANE; BULLOUS SKIN DISEASE; CELL ADHESION; EPIDERMOLYSIS BULLOSA ACQUISITA; EXTRACELLULAR MATRIX; HUMAN; IMMUNOLOGY; MOUTH DISEASE; MUCOUS MEMBRANE PEMPHIGOID; PATHOLOGY; PEMPHIGUS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BASEMENT MEMBRANE; CELL ADHESION; EPIDERMOLYSIS BULLOSA ACQUISITA; EXTRACELLULAR MATRIX; HUMANS; IMMUNOGLOBULIN A; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOUTH DISEASES; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGUS; SKIN DISEASES, VESICULOBULLOUS;

EID: 0031262841     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-2104(97)90269-9     Document Type: Review

References (171)

1. Lever WP. Pemphigus and pemphigoid: a review of the advances made since-1964. J Am Acad Dermatol 1979;1:2-31.
2. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. 1993. Dermatology in general medicine, 4th ed. Vol I and II. New York: McGraw-Hill, Inc. p. 577-669.
3. Anhalt G, Kim S, Stanley J, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990;323:1729-35.
4. Shoda Y, Hashimoto K, Matsuoka Y, Yoshikawa K. A case of pemphigus vulgaris in a six-year-old girl. J Dermatol 1991;18:175-7.
5. Laskaris G, Stoufi E. Oral pemphigus vulgaris in a 6-year-old girl. Oral Surg Oral Med Oral Pathol 1990;69:609-13.
6. Orlowski WA, Bressman E, Doyle JL, Chasens AI. Chronic pemphigus vulgaris of the gingiva. J Periodontol 1983;54:685-9.
7. Zegarelli DJ, Zegarelli EV. Intraoral pemphigus vulgaris. Oral Surg Oral Med Oral Pathol 1977;44:384-93.
8. Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris-incidence in Jews of different ethnic groups according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol 1974;38:382-7.
9. Siegel MA, Balciunas BA, Kelly M, Serio FG. Diagnosis and management of commonly occurring oral vesiculoerosive disorders. Cutis 1991;47:39-43.
10. Ahmed RA, Mohimen A, Yunis EJ, et al. Linkage of pemphi-gus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 1993;177:419-24.
11. Gilmore HK. Early detection of pemphigus vulgaris. Oral Surg 1978;46:641-4.
12. Mariotti A. Desquamative gingivitis: revisited. Todays FDA 1991;3:1C-2C.
13. Goodman H. Nikolsky sign. Arch Dermatol Syphilol 1953;68:334-5.
14. Hashimoto K, Lever WF. An electron microscopic study of pemphigus vulgaris of the mouth and skin with special reference to the intercellular cement. J Invest Dermatol 1967;48:540-52.
15. Director W. Pemphigus vulgaris: a clinicopathological study. Arch Dermatol Syphilol 1952;65:155-69.
16. Emmerson RW, Wilson-Jones E. Eosinophilic spongiosis in pemphigus. Arch Dermatol 1968;97:252-7.
17. Grando SA, Terman AK, Stupina AS, Glukhenky BT, Romanenko AB. Ultrastructural study of clinically uninvolved skin of patients with pemphigus vulgaris. Clin Exp Dermatol 1991;16:359-63.
18. Jordon RE. Direct immunofluorescent studies of pemphigus and bullous pemphigoid. Arch Dermatol 1971;103:486-90.
19. Kim YH, Geoghegan WD, Jordon RE. Pemphigus immunoglobulin G subclass autoantibodies: studies of reactivity with cultured human keratinocytes. J Lab Clin Med 1990;115:324-31.
20. Fitzpatrick RE, Newcomer VD. The correlation of disease activity and antibody titers in pemphigus. Arch Dermatol 1980;116:285-90.
21. Acosta E, Gilkes JH, Ivanyi L. Relationship between the serum autoantibody titers and the clinical activity of pemphigus vulgaris. Oral Surg Oral Med Oral Pathol 1985;60:611-4.
22. Hashimoto T, Sugiura M, Kurihara S, Nishikawa T. In vitro complement activation by intercellular antibodies. J Invest Dermatol 1982;78:316-8.
23. Sams WM, Schur PH. Studies of the antibodies in pemphigoid and pemphigus. J Lab Clin Med 1973;82:249-54.
24. Morioka S, Lazarus GS, Jensen PJ. Involvement of urokinasetype plasminogen activator in acantholysis induced by pemphigus IgG. J Invest Dermatol 1987;89:474-7.
25. Hashimoto K, Shafran KM, Webber PS, Lazarus GS, Singer KH. Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells: a proposed mechanism for the loss of epidermal cohesion and blister formation. J Exp Med 1983;157:259-72.
26. Anhalt GJ, Patel HP, Labib RS, Diaz LA, Proud D. Dexamethasone inhibits plasminogen activator in experimental pemphigus in vivo but does not block acantholysis. J Immunol 1986;136:113-7.
27. Stanley J, Yaar M, Hawley-Nelson P, Katz S. Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. J Clin Invest 1982;70:281-8.
28. Burge SM, Wilson DL, Dean D, Wojnarowska F. An immunohistological study of desmosomal components in pemphigus. Br J Dermatol 1993;128:363-70.
29. Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol 1996;106:351-5.
30. Cowin P, Kapprell, HP, Franke W, Tamkun J, Hynes RO. Plakoglobin: a protein common to different kinds of intercellular adhering junctions. Cell 1986;46:1063-73.
31. Barlow Y, Wray D. Ultrastructural alterations associated with in vivo and in vitro bound pemphigus antibodies in cultured oral epithelial cells. J Oral Path Med 1991;20:241-4.
32. Amagai M. Pemphigus: autoimmunity to epidermal cell adhesion molecules. Adv Dermatol 1996;11:319-53.
33. Amagai M, Karpati S, Prussick R, et al. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992;90:919-26.
34. Lamey PJ, Rees TD, Binnie WH, Wright JM, Rankin KV, Simpson NB. Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy. Oral Surg Oral Med Oral Pathol 1992;74:54-7.
35. Bondesson L, Hammar H. Treatment of pemphigus vulgaris with cyclosporine. Dermatologica 1990;181:308-10.
36. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses: a clinical and immunopathologic analysis. Arch Dermatol 1990;126:339-50.
37. Piamphongsant T, Ophaswongse S. Treatment of pemphigus. Int J Dermatol 1991;30:139-46.
38. Pandya AG, Sontheimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol 1992;128:1626-30.
39. Butler RT, Kalkwarf KL, Kaldahl W. Drug-induced gingival hyperplasia: phenytoin, cyclosporine, and nifedipine. J Am Dent Assoc 1987;114:56-9.
40. Edelson RL. Photopheresis: a clinically relevant immunobiologic response modifier. Ann N Y Acad Sci 1991;636:154-64.
41. Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol 1992;26:779-80.
42. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. Arch Dermatol 1996;132:203-12.
43. Korman N. Pemphigus. J Am Acad Dermatol 1988;18:1219-38.
44. Kaplan RP, Potter TS, Fox JN. Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 1992;26(2 pt 2):364-6.
45. Korman NJ, Eyre RW, Zone J, Stanley JR. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol 1991;96:273-6.
46. Kantiakis J, Wang YZ, Roche P, et al. Immunohistopathological study of autoimmune pemphigus. Clin Lab Invest 1994;188: 282-5.
47. Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin 1993;11:473-81.
48. Fullerton SH, Woodley DT, Smoller BR, Anhalt GJ. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. JAMA 1992;267:1500-2.
49. Joly P, Thomine E, Gilbert D, et al. Overlapping distribution of autoantibody specificities in paraneoplastic pemphigus and pemphigus vulgaris. J Invest Dermatol 1994;103:65-72.
50. Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 1995;32:441-7.
51. Lui AY, Valenzuela R, Helm TN, et al. Indirect immunofluorescence on rat bladder transitional epithelium: a test with high specificity for paraneoplastic pemphigus. J Am Acad Dermatol 1993;28:696-9.
52. Oursler JR, Labib RS, Ariss-Abodo L, Burke T, O'Keefe EJ, Anhalt GJ. Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest 1992;89:1775-82.
53. Helm TN, Camisa C, Valenzuela R, Allen CM. Paraneoplastic phemphigus: a distinct autoimmune vesiculobullous disorder associated with neoplasia. Oral Surg Oral Med Oral Pathol 1993;75:209-13.
54. Shklar G, McCarthy PL. Oral lesions of mucous membrane pemphigoid: a study of 85 cases. Arch Otolaryngol 1971;84: 354-64.
55. Eversole LR. Immunopathology of oral mucosal ulcerative, desquamative, and bullous diseases: selective review of the literature. Oral Surg Oral Med Oral Pathol 1994;77:555-71.
56. Liu HN, Su WP, Rogers RS. Clinical variants of pemphigoid. Int J Dermatol 1986;25:17-27.
57. Gallagher C, Shklar G. Oral involvement in mucous membrane pemphigoid. Clin Dermatol 1987;5:18-27.
58. Mondino BJ, Brown SI. Rabin BS. HLA antigens in ocular cicatricial pemphigoid. Arch Ophthalmol 1979;97:479-80.
59. Silverman S, Gorsky M, Lozada-Nur F, Liu A. Oral mucous membrane pemphigoid: a study of sixty-five patients. Oral Surg Oral Med Oral Pathol 1986:61:233-7.
60. Mutasim DF, Pelc NJ, Anhalt GJ. Cicatricial pemphigoid. Dermatol Clin 1993;1:499-510.
61. Anhalt GJ. Bullous skin lesions. In: Frank MM, Austen KF, Clamen HN, Unanue ER, editors. Samter's immunologic diseases. Boston: Little, Brown; 1995. p. 1179-91.
62. Miller BA, Gornitsky M: Benign mucous membrane pemphigoid: a case report. J Can Dent Assoc 1991;57:799-800.
63. Person JR, Rogers RS. Bullous and cicatricial pemphigoid: clinical histopathologic and immunopathologic correlations. Mayo Clin Proc 1977;52:54-64.
64. Shklar G, Meyer I, Zacarian SA. Oral lesions in bullous pemphigoid. Arch Dermatol 1969;99:663-70.
65. Laskaris G, Sklavounou A, Stratigos J. Bullous pemphigoid, cicatricial pemphigoid and pemphigus vulgaris. Oral Surg 1982;54:656-62.
66. Dahl MGC, Cook LJ. Lesions induced by trauma in pemphigoid. Br J Dermatol 1979;101:469-73.
67. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986;84:527-663.
68. Williams DM, Leonard JN, Wright P, et al. Benign mucous membrane (cicatricial) pemphigoid revisited: a clinical and immunological reappraisal. Br Dent J 1984;157:313-6.
69. Williams D. Vesiculo-bullous mucocutaneous disease: benign mucous membrane and bullous pemphigoid. J Oral Pathol Med 1990;19:16-23.
70. Bedane C, Prost C, Bernard P, Catanzano G, Bonnetblanc JM, Dubertret L. Cicatricial pemphigoid antigen differs from bullous pemphigoid antigen by its exclusive extracellular localization: a study by indirect immunoelectronmicroscopy. J Invest Dermatol 1991;97:3-9.
71. Laskaris G, Angelopoulos A. Cicatricial pemphigoid: direct and indirect immunofluorescent studies. Oral Surg Oral Med Oral Pathol 1981;51:48-54.
72. Laskaris G, Demetriou N, Angelopoulos A. Immunofluorescent studies in desquamative gingivitis. J Oral Pathol 1981;10:398-401.
73. Anhalt GJ, Morrison L. Pemphigoid: bullous, gestational, and cicatricial. In: Provost T. Weston W, editors. Bullous diseases. St Louis: CV Mosby Co; 1993. p. 97-113.
74. Siegel MA, Anhalt GJ. Direct immunofluorescence of detached gingival epithelium for diagnosis of cicatricial pemphigoid: report of five cases. Oral Surg Oral Med Oral Pathol 1993;75: 296-302.
75. Gammon WR, Merritt CC, Lewis DM. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol 1982;78:285-90.
76. Fine JD, Neises GR, Katz SI. Immunofluorescence and immunoelectron microscopic studies in cicatricial pemphigoid. J Invest Dermatol 1984;82:39-43.
77. Horiguchi Y, Tanaka T, Akioka N, et al. Restriction of cicatricial pemphigoid antigens to the lamina densa: confirmation by indirect immunoelectron microscopy. J Dermatol 1992;19:449-55.
78. Kirtschig G, Marinkovich MP, Burgeson RE, Yancey KB. Antibasement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. J Invest Dermatol 1995;105:543-8.
79. Domloge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey B. Epiligrin, a major human keratinocyte integrin ligand, is targeted by autoantibodies in patients with a form of cicatricial pemphigoid. J Invest Dermatol 1992;90: 1628-33.
80. Lazarova Z, Yancey KB. Reactivity of autoantibodies from patients with defined subepidermal bullous diseases against 1 mol/L salt-split skin: specificity, sensitivity, and practical considerations. J Am Acad Dermatol 1996;35:398-403.
81. Shimizu H, Masunaga T, Ishiko A, et al. Autoantibodies from patients with cicatricial pemphigoid target different sites in epidermal basement membrane. J Invest Dermatol 1995;104:370-3.
82. Mueller S, Klaus-Kovtun V, Stanley JR. A 230-kD basic protein is the major bullous pemphigoid antigen. J Invest Dermatol 1989;92:33-8.
83. Eady RA. The hemidesmosome: a target in auto-immune bullous disease. Dermatol 1994;189:38-41.
84. Balding SD, Prost C, Diaz LA, et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol 1996;106:141-6.
85. Bernard P, Prost C, Durepaire N, Basset-Seguin N, Didierjean L, Saurat JH. The major cicatricial pemphigoid antigen is a 180kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen. J Invest Dermatol 1992;99: 174-9.
86. Chan LS, Hammerberg C, Cooper KD. Cicatricial pemphigoid: identification of two distinct sets of epidermal antigens by Ig A and Ig G class circulating autoantibodies. Arch Dermatol 1990;126:1466-8.
87. Lamey PJ, Rees TD, Binnie WH, Rankin KV. Mucous membrane pemphigoid: treatment experience at two institutions. Oral Surg Oral Med Oral Pathol 1992;74:50-3.
88. Aufdemorte TB, Villez RL, Parel SM. Modified topical steroid therapy for the treatment of oral mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol 1985;59:256-60.
89. Rogers RS, Seehafer JR, Perry HO. Treatment of cicatricial pemphigoid with Dapsone. J Am Acad Dermatol 1982;5:215-23.
90. Barranco VP. Inhibition of lysosomal enzymes by Dapsone. Arch Dermatol 1974;110:563-6.
91. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992;98:135-40.
92. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994;130:753-8.
93. Poskitt L, Wojnarowska F. Treatment of cicatricial pemphigoid with tetracycline and nicotinamide. Clin Exp Dermatol 1995;20:258-9.
94. Shore JW, Foster CS, Westfall T, Rubin PA. Results of buccal mucosal grafting for patients with medically controlled ocular cicatricial pemphigoid. Ophthalmology 1992;99:383-95.
95. Nisengard RJ, Rogers RS III. The treatment of desquamative gingival lesions. J Periodontol 1987;58:167-72.
96. Lass JH, Thoft RA, Dohlman CH. Idoxuridine-induced conjunctival cicatrization. Arch Ophthalmol 1983;101:747-50.
97. Shuttleworth D, Graham-Brown RA, Hutchinson PE, Jolliffe DS. Cicatricial pemphigoid in D-penicillamine treated patients with rheumatoid arthritis-a report of three cases. Clin Exp Dermatol 1985;10:392-7.
98. Fine R, Weathers D. Desquamative gingivitis: a form of cicatricial pemphigoid? Br J Dermatol 1971;102:393-9.
99. Katz SI, Strober W. The pathogenesis of dermatitis herpetiformis. J Invest Dermatol 1978;70:63-75.
100. vanJoost T, Faber WR, Westerhof W, deMari F. Linear dermoepidermal IgA deposition in bullous pemphigoid. Acta Derm Venereol 1979;59:463-5.
101. Wilson BD, Beutner EH, Kumar V, Chorleski TP, Jablonska S. Linear IgA bullous dermatitis: an immunologically defined disease. J Dermatol 1985;24:569-74.
102. Chorzelski T, Jablonska S. Evolving concept of IgA linear dermatosis. Semin Dermatol 1988;7:225-32.
103. Mobacken H, Kastrup W, Ljunghall KJ, et al. Linear IgA dermatosis: a study of ten adult patients. Acta Derm Venereol 1983;63:123-8.
104. Leonard JN, Wright P, Williams DM, et al. The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br J Dermatol 1984;110:307-14.
105. Wojnarowska F, Marsden RA, Bhogal B, Black MM, Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear Ig A disease of adults. J Am Acad Dermatol 1988;19:792-805.
106. Edwards S, Wojnarowska F, Armstrong LM. Chronic bullous disease of childhood with oral mucosal scarring. Clin Exp Dermatol 1991;16:41-3.
107. Weisenfeld D, Martin A, Scully C, Thomson J. Oral manifestations in linear IgA disease. Br Dent J 1982;153:398-9.
108. Hietane J, Reunala T. IgA deposits in the oral mucosa of patients with dermatitis herpetiformis and linear IgA disease. Scand J Dent Res 1984;92:230-4.
109. Porter SR, Bain SE, Scully CM. Linear IgA disease manifesting as recalcitrant desquamative gingivitis. Oral Surg Oral Med Oral Pathol 1992;74:179-82.
110. Chan LS, Regezi JA, Cooper KD. Oral manifestations of linear IgA disease. J Am Acad Dermatol 1990;22:362-5.
111. Hendrix JD, Mangum KL, Zone JJ, Gammon WR. Cutaneous IgA deposits in bullous diseases function as ligands to mediate adherence of activated neutrophils. J Invest Derm 1990;94:667-72.
112. Blenkinsopp WK, Haffenden GP, Fry L, Leonard JN. Histology of linear IgA disease, dermatitis herpetiformis, and bullous pemphigoid. Am J Dermatopathol 1983;5:547-54.
113. Smith SB, Harrist TJ, Murphy GF, et al. Linear IgA bullous dermatosis v dermatitis herpetiformis, quantitative measurements of dermoepidermal alterations. Arch Dermatol 1984;120:324-8.
114. Flotte TJ, Olbricht SM, Collins AB, Harrist TJ. Immunopathologic studies of adult linear IgA bullous dermatosis. Arch Pathol Lab Med 1985;109:457-9.
115. Wojnarowska F, Delacroix D, Gengoux P. Cutaneous IgA subclasses in dermatitis herpetiformis and linear IgA disease. J Cutan Pathol 1988;15:272-5.
116. Leonard JN, Haffenden GP, Unsworth Dj, Ring NP, Holborow EJ, Fry L. Evidence that the IgA in patients with linear IgA disease is quantitatively different from that of patients with dermatitis herpetiformis. Br J Dermatol 1984;110:315-21.
117. Leonard JN, Haffenden GP, Ring NP, et al. Linear IgA disease in adults. Br J Dermatol 1982;107:301-16.
118. Petersen JM, Cammon RW, Briggaman RA. A case of linear IgA disease presenting initially with IgG immune deposits. J Am Acad Dermatol 1986;14:1014-9.
119. Isonpkami M, Hashimoto K, Horiguchi Y, Yoshikawa K. A case of linear IgA bullous dermatosis with atypical clinical and ultrastructural manifestations. J Dermatol 1994;21:268-72.
120. Lawley TJ, Strober W, Yaoita H, Katz SI. Small intestinal biopsies and HLA types in dermatitis herpetiformis patients with granular and linear IgA skin deposits. J Invest Dermatol 1980;74:9-12.
121. Chan LS, Traczyk T, Taylor MS, et al. Linear IgA bullous dermatosis. Characterization of a subset of patients with concurrent IgA and IgG anti-basement membrane autoantibodies. Arach Dermatol 1995;131:1432-47.
122. Zone JJ, Smith EP, Powell D, et al. Antigenic specificty of antibodies from patients with linear basement membrane deposition of IgA. Dermatol 1994;189(suppl 1):64-6.
123. Smith EP, Zone JJ. Dermatitis herpetiformis and linear IgA bullous dermatosis. Dermatol Clin 1993;11:511-26.
124. Rantala I, Hietanen J, Soidinmaki H, Reunala T. Immunoelec tron microscopic findings in oral mucosa of patients with dermatitis herpetiformis and linear IgA disease. Scand J Dent Res 1985;93:243-8.
125. Wojnarowska F, Allen J, Collier P. Linear IgA disease: a heterogeneous disease. Dermatology 1994:189(suppl 1):52-6.
126. Zone JJ, Taylor TB, Meyer LJ. Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. J Clin Invest 1990;85:812-20.
127. Haftek M, Zone JJ, Taylor TB, Kowalewski C, Chorzelski TP. Immunogold localization of the 97-kD antigen of linear IgA bullous dermatosis (LABD) detected with patients' sera. J Invest Dermatol 1994;103:656-9.
128. Zambruno G, Manca V, Kanitakis J, Cozzani E, Nicolas JF, Giannetti A. Linear IgA bullous dermatosis with autoantibodies to a 290 kD antigen of anchoring fibrils. J Am Acad Dermatol 1994;31:884-8.
129. Bhogal B, Wojnarowska F, Marsden RA, Das A, Black MM, McKee PH. Linear IgA bullous dermatosis of adults and children: an immunoelectron microscopic study. Br J Dermatol 1987;117:289-96.
130. Provost C, Colonna De Leca A, Combemale P, et al. Diagnosis of adult linear IgA dermatosis by immunoelectronmicrosopy in 16 patients with linear IgA deposits. J Invest Dermatol 1989;92:39-45.
131. Nishikawa T. A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies. Br J Dermatol 1996;134:336-9.
132. Marinkovich MP, Taylor TB, Keene Dr, Burgeson RE, Zone JJ. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996;106:734-8.
133. Marsden RA. The treatment of benign chronic bullous dermatosis of childhood, and dermatitis herpetiformis and bullous pemphigoid beginning in childhood. Clin Exp Dermatol 1982;7:653-63.
134. Carpenter S, Berg D, Sidhu-Malik N, Hall RP 3d, Rico MJ. Vancomycin-associated linear IgA dermatosis. J Am Acad Dermatol 1992;26:45-8.
135. Kuechle MK, Stegemeir E, Maynard B, Gibson LE, Leiferman KM, Peters MS. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol 1994;30:187-92.
136. McWhirter JD, Hashimoto K, Kumar V, Fayne S, Ito K. Linear IgA bullous dermatosis related to lithium carbonate. Arch Dermatol 1987;123:1120-2.
137. Klein LE, Shmunes E, Carter JB, Walsh MY. Linear IgA bullous dermatosis related to captopril treatment. Cutis 1989;44:393-6.
138. Gammon WR. Epidermolysis bullosa acquisita. Semin Dermatol 1988;7:218-24.
139. Gammon WR, Briggaman RA. Epidermolysis bullosa acquisita and bullous systemic lupus erythematosus: diseases of autoimmunity to type VII collagen. Dermatol Clin 1993;11:535-47.
140. Gammon WR, Briggaman RA, Wheeler CE Jr. Epidermolysis bullosa aquisita presenting as an inflammatory bullous disease. J Am Acad Dermatol 1982;7:382-7.
141. Gammon WR, Briggaman RA, Woodley DT, Heald PW, Wheeler CE Jr. Epidermolysis bullosa acquisita-a pemphigoidlike disease. J Am Acad Dermatol 1984;11:820-32.
142. Dahl MGC. Epidermolysis bullosa acquisita-a sign of cicatricial pemphigoid? Br J Dermatol 1979;101:475-83.
143. Lang PG Jr. Tapert MJ. Severe ocular involvement in a patient with epidermolysis bullosa acquisita. J Am Acad Dermatol 1987;16:439-43.
144. Yaoita H, Briggaman RA, Lawley TJ. Epidermolysis bullosa acquisita: ultrastructural and immunological studies. J Invest Dermatol 1981;76:288-92.
145. Kushniruk W. The immunopathology of epidermolysis bullosa acquisita. Can Med Assoc J 1973;108:1143-6.
146. Mooney E, Gammon WR. Heavy and light chain isotypes of epidermolysis bullosa acquisita antibodies. Clin Res 1987;35:705A.
147. Fine JD, Tyring S, Gammon WR. The presence of intralamina lucida blister formation in epidermolysis bullosa acquisita: possible role of leukocytes. J Invest Dermatol 1989;92:27-32.
148. Gammon WR, Briggaman RA, Inman AO, Queen LL, Wheeler CE Jr. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by direct immunofluorescence on 1.0M sodium chloride-separated skin. J Invest Dermatol 1984;82:139-44.
149. Gammon WR, Kowalewski C, Chorzelski TP, et al. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquista. J Am Acad Dermatol 1990;22:664-70.
150. Gibbs RB, Minus HR. Epidermolysis bullosa acquisita with electron microscopical studies. Arch Dermatol 1975;111:215-20.
151. Woodley DT, Burgeson RE, Lunstrum GP, Reese MJ, Bruckner-Tuderman L, Briggaman RA. The epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest 1988;81:683-7.
152. Woodley DT, O'Keefe EJ, Reese MJ, Mechanic GL, Briggaman RA, Gammon WR. Epidermolysis bullosa acquisita antigen, a new major component of cutaneous basement membrane, is a glycoprotein with collagenous domains. J Invest Dermatol 1986;86:668-72.
153. Jones DA, Hunt SW 3rd, Prisayanh PS, Briggaman RA, Gammon WR. Immunodominant autoepitopes of type VII collagen are short, paired peptide sequences within the fibronectin type III homology region of the noncollagenous (NC1) domain. J Invest Dermatol 1995;104:231-5.
154. Tanaka T, Furukawa F, Imamura S. Epitope mapping for epidermolysis bullosa acquisita autoantibody by molecularly cloned cDNA for type VII collagen. J Invest Dermatol 1994; 102:706-9.
155. Marcelus CJ, DeJong M, Bruins S, et al. Bullous pemphigoid and epidermolysis bullosa acquisita. Arch Dermatol 1996; 132:151-7.
156. De Jong MC, Bruins S, Heeres K, Jonkman MF, Nieboer C, Boorsma DM, et al. Bullous pemphigoid and epidermolysis bullosa acquisita: differentiation by fluorescence overlay antigen mapping. Arch Dermatol 1996;132:151-7.
157. Connolly SM, Sander HM. Treatment of epidermolysis bullosa acquisita with cyclosporine. [Letter]. J Am Acad Dermatol 1987;16:890.
158. Roholt NS, Lapiere JC, Wang JI, Bernstein LJ, Woodley DT, Eramo LR. Localized linear bullous eruption of systemic lupus erythematosus in a child. Pediatr Dermatol 1995;12:138-44.
159. Boh E, Roberts LJ, Liew TS, et al. Epidermolysis bullosa acquisita preceding the development of systemic lupus erythematosus. J Am Acad Dermatol 1990;22:587-93.
160. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
161. Camisa C, Sharma HM. Vesiculobullous systemic lupus erythematosus. J Am Acad Dermatol 1983;9:924-33.
162. Camisa C. Vesiculobullous systemic lupus erythematosus. J Am Acad Dermatol 1988;18:93-100.
163. Penneys NS, Wiley HE III. Herpetiform blisters in systemic lupus erythematosus. Arch Dermatol 1979;115:1427-8.
164. Briggaman RA, Gammon RW. Epidermolysis bullosa acquisita and other acquired blistering diseases manifesting autoimmunity to type VII collagen. In: Provost T, Weston W, editors. Bullous diseases. St Louis: CV Mosby Co; 1993. p. 144-7.
165. Gammon WR, Fine JD, Briggaman RA. Autoimmunity to type VII collagen: features and role in basement membrane injury. In: Fine JD, editor. Bullous diseases. New York: Igaku-Shoin; 1993. p. 75-89.
166. Gammon WR, Woodley DT, Dole KC, Briggaman RA. Evidence that anti-basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognize epidermolysis bullosa acquisita autoantigen. J Invest Dermatol 1985;84:472-6.
167. Barton DD, Fine JD, Gammon WR, Sams WM Jr. Bullous systemic lupus erythematosus: an unusual clinical course and detectable circulation autoantibodies to the epidermolysis bullosa acquisita antigen. J Am Acad Dermatol 1986;15:369-73.
168. Yell JA, Allen J, Wojnarowska F, Kirtschig G, Burge SM. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995;132:921-8.
169. Tani M, Shimizu R, Ban M, Murata Y, Tamaki A. Systemic lupus erythematosus with vesiculobullous lesions: Immunoelectron microscopic studies. Arch Dermatol 1984; 120:1497-501.
170. Olansky AJ, Briggaman RA, Gammon WR, Kelly TF, Sams WM Jr. Bullous systemic lupus erythematosus. J Am Acad Dermatol 1982;7:511-20.
171. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993;100:28S-34S.